Lv7
5000 积分 2022-09-16 加入
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes(SUSTAIN 3):A 56-Week，Open-Label，Randomized Clinical Trial
17天前
已完结
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes(SUSTAIN 7):a randomised，open-label，phase 3b trial
17天前
已完结
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
1个月前
已完结
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial
4个月前
已完结
LB0008 SAP-001, A FIRST –IN-CLASS COMPOUND TARGETING A RENAL URATE TRANSPORTER, SHOWS POTENT SERUM URATE-LOWERING EFFECTS AND FAVORABLE SAFETY PROFILE IN A US PHASE 2b STUDY IN PATIENTS WITH REFRACTORY GOUT WITH OR WITHOUT PALPABLE TOPHI
4个月前
已完结
Amitriptyline versus placebo in postherpetic neuralgia
6个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
7个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
7个月前
已完结
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system
9个月前
已完结
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
9个月前
已完结
皖公网安备34019202002308
